AbbVie
ABBV
3,080 hedge funds and large institutions have $165B invested in AbbVie in 2023 Q2 according to their latest regulatory filings, with 151 funds opening new positions, 1,141 increasing their positions, 1,433 reducing their positions, and 183 closing their positions.
46% more call options, than puts
Call options by funds: $2.74B | Put options by funds: $1.87B
0.45% less ownership
Funds ownership: 69.77% → 69.32% (-0.45%)
2% less funds holding
Funds holding: 3,142 → 3,080 (-62)
17% less first-time investments, than exits
New positions opened: 151 | Existing positions closed: 183
20% less repeat investments, than reductions
Existing positions increased: 1,141 | Existing positions reduced: 1,433
21% less capital inflows, than outflows
Capital inflows: $6.01B | Capital outflows: $7.62B
43% less funds holding in top 10
Funds holding in top 10: 303 → 172 (-131)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$453M |
| 2 |
Barclays
London,
United Kingdom
|
+$305M |
| 3 |
D.E. Shaw & Co
New York
|
+$225M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$185M |
| 5 |
Two Sigma Investments
New York
|
+$176M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$647M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$465M |
| 3 |
Janus Henderson Group
London,
|
-$406M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$360M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$291M |
ABBV Hedge Fund Activity: Q2 2023 in Review
3,080 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2023, worth a combined $165B — down 16% from $197B a quarter earlier.
Sellers outnumbered buyers: 183 funds closed out of ABBV and 151 opened new positions — a net loss of 32 holders — while 1,433 trimmed existing stakes and 1,141 added.
The largest buyer was Ontario Teachers' Pension Plan Board, adding an estimated $453M. The largest seller was T. Rowe Price Associates, cutting an estimated $647M.
- 3,080 institutional investors held AbbVie (ABBV) as of Q2 2023, down from 3,142 in Q1 2023.
- Funds reported $165B of AbbVie stock for Q2 2023, down 16% quarter-over-quarter.
- 151 funds opened new AbbVie positions in Q2 2023 and 183 closed out, a net change of -32 holders.
- The largest AbbVie buyer in Q2 2023 was Ontario Teachers' Pension Plan Board, an estimated $453M added.
- The largest AbbVie seller in Q2 2023 was T. Rowe Price Associates, an estimated $647M sold.
Based on aggregated 13F filings for Q2 2023.